Advanced prostate cancer.
Subcutaneous; given in abdomen region, starting dose is 240mg in two doses, while maintenance dose is 80mg administered every 28 days.
Known hypersensitivity to degarelix, pregnancy.
Paediatric: Safety and effectiveness in paediatric group not yet established. Pregnancy: Contraindicated. Lactation: Not known if excereted in milk. Elderly: Increase sensitivity, use with caution.
Pain, erythema , swelling, induration and nodule at the site , weight increase, fatigue, chills, hot flushes, increased liver enzymes, hypertension, arthralgia.
Data not sufficient.